Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-hepatitis b virus gene medicament based on siRNA pool interference and mediated by complex carrier

A composite vector, viral gene technology, used in antiviral agents, DNA/RNA fragments, gene therapy, etc.

Inactive Publication Date: 2008-12-17
淮安市第四人民医院
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, most of the synthetic siRNA or siRNA expression vectors are introduced into cells by direct injection or liposome encapsulation, but the effective epitope protein in the hepatitis B surface antigen expressed by hepatitis B virus is biologically linked with cationic liposomes to mediate RNAi The study of entering liver cells has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-hepatitis b virus gene medicament based on siRNA pool interference and mediated by complex carrier
  • Anti-hepatitis b virus gene medicament based on siRNA pool interference and mediated by complex carrier
  • Anti-hepatitis b virus gene medicament based on siRNA pool interference and mediated by complex carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0042] Below in conjunction with specific examples, further elaborate the present invention in detail, the prominent substantive features and positive effects of the present invention can be manifested from the following examples, but they do not limit the present invention in any way.

[0043] Material

[0044] psiSTRIKE TM The plasmid kit was purchased from Promega Company, the antibiotic G418 was purchased from Sigma-Aldrich Company, bovine albumin serum (BSA) (component V, purity>98%) was purchased from USB Company, DMEM (Dulbecco's modified eagle's medium), penicillin G ( 5000 units / ml), Trypsin-EDTA, Trizol, DNase I, HBsAg epitope protein-cationic liposome composite carrier was synthesized by ABI company, PureLink TM Viral RNA / DNA kit, mouse monoclonal anti-HBsAg and Alexa Fluor 488 goat anti-mouse IgG were purchased from Invitrogen, and restriction enzymes (PstI, EcoRI, ClaI, BsrGI, SgfI and BglII.) were purchased from New England Biolabs Company, reverse transcriptas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a siRNA interference-based anti-HBV gene-based drug mediated by complex carriers. Based on the characteristic of HBV and expression products thereof, active epitope protein in HBsAg expressed by HBV is biologically linked with cationic liposome and specially binds with hepatic cell surface receptors with the help of the epitope protein in the HBsAg to induce RNAi to enter hepatic cells; meanwhile, the meltability of bilayers of the cationic liposome and the cytolipin is used for increasing the efficiency of an siRNA expressed carrier entering into the hepatic cells. The drug of the invention can improve the effectiveness of the siRNA, biological stability in the human body, safety and effective targeting delivery and can be used in the clinical treatment.

Description

technical field [0001] The present invention relates to a kind of RNAi anti-hepatitis B virus drug, that is, the effective epitope protein in the hepatitis B surface antigen expressed by hepatitis B virus is biologically linked with cationic liposome to mediate RNAi into the liver cell. The invention specifically relates to a drug based on siRNA Composite carrier-mediated anti-HBV gene drug for pool interference. Background technique [0002] Persistent infection with hepatitis B virus (HBV) is an important health problem worldwide. There are currently about 350 million infected people in the world, 75% of which are located in the Asia-Pacific region. The 1992-1995 national viral hepatitis serum epidemiological survey showed that the infection rate of hepatitis B virus among Chinese population was 57.6%, and the carrier rate of hepatitis B virus was 9.75%. Based on this, it is estimated that 690 million people in the country have ever been infected with hepatitis B virus, o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K47/48A61K47/24A61P1/16A61P31/20C12N15/11A61K47/54A61K47/69
Inventor 陈勇
Owner 淮安市第四人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com